［1］ BRAY F,LAVERSANNE M,SUNG HN,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2024,74(3):229-263.
［2］ VON MG,HUANG CS,MANO MS,et al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer［J］.N Engl J Med,2019,380(7):617-628.
［3］ VON MG,SCHNEEWEISS A,LOIBL S,et al.Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer(GeparSixto;GBG 66):a randomised phase 2 trial［J］.Lancet Oncol,2014,15(7):747-756.
［4］ CORTES J,CESCON DW,RUGO HS,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer(KEYNOTE-355):a randomised,placebo-controlled,double-blind,phase 3 clinical trial［J］.Lancet,2020,396(10265):1817-1828.
［5］ TURNER NC,SLAMON DJ,RO J,et al.Overall survival with palbociclib and fulvestrant in advanced breast cancer［J］.N Engl J Med,2018,379(20):1926-1936.
［6］ ANSARI MJ,BOKOV D,MARKOV A,et al.Cancer combination therapies by angiogenesis inhibitors;a comprehensive review［J］.Cell Commun Signal,2022,20(1):49.
［7］ LI Y,LIN M,WANG S,et al.Novel angiogenic regulators and antiangiogenesis drugs targeting angiogenesis signaling pathways:Perspectives for targeting angiogenesis in lung cancer［J］.Front Oncol,2022,12:842960.
［8］ LI J,QIN S,XU J,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］.J Clin Oncol,2016,34(13):1448-1454.
［9］ TEJPAR S,STINTZING S,CIARDIELLO F,et al.Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer:Retrospective analyses of the CRYSTAL and FIRE-3 trials［J］.JAMA Oncol,2017,3(2):194-201.
［10］ PENSON RT,MOORE KM,FLEMING GF,et al.A phase Ⅱ study of ramucirumab(IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian,fallopian tube or primary peritoneal carcinoma［J］.Gynecol Oncol,2014,134(3):478-485.
［11］ SHEN G,ZHENG F,REN D,et al.Anlotinib:A novel multi-targeting tyrosine kinase inhibitor in clinical development［J］.J Hematol Oncol,2018,11(1):120.
［12］ SU Y,LUO B,LU Y,et al.Anlotinib induces a T cell inflflamed tumor microenvironment by facilitating vessel normalization and enhances the effificacy of PD-1 checkpoint blockade in neuroblastoma［J］.Clin Cancer Res,2022,28(4):793-809.
［13］ ZHONG C,CHEN F,YANG J,et al.Pharmacokinetics and disposition of anlotinib,an oral tyrosine kinase inhibitor,in experimental animal species［J］.Acta Pharmacologica Sinica,2018,39:1048-1063.
［14］ LIN B,SONG X,YANG D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRβ and FGFR1［J］.Gene,2018,654:77-86.
［15］ KAKIUCHI KS,LAPPIN PB,HEINTZ C,et al.Expression of proto-oncogene cFMS protein in lung,breast,and ovarian cancers［J］.Applied Immunohistochemistry & Molecular Morphology,2014,22:188-199.
［16］ ASHTON S,SONG YH,NOLAN J,et al.Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo［J］.Science Translational Medicine,2016,8:325ra17.
［17］ WANG C,CHEN J,CAO W,et al.Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT,mTOR and Notch pathways［J］.European Journal of Pharmacology,2016,779:1-7.
［18］ AMBROGIO C,GOMEZ LG,FALCONE M,et al.Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma［J］.Nature Medicine,2016,22:270-277.
［19］ SOTOHY B,NAGY JA,DVORAK HF.Anti-VEGF/VEGFR therapy for cancer:reassessing the target ［J］.Cancer Res,2012,72(8):1909-1914.
［20］ FOLKMAN J.Tumor angiogenesis:therapeutic implications［J］.N Engl J Med,1971,285(21):1182-1186.
［21］ YOSHIJI H,GOMEZ DE,SHIBUYA M,et al.Expression of vascular endothelial growth factor,its receptor,and other angiogenic factors in human breast cancer［J］.Cancer Res,1996,56(9):2013-2016.
［22］ YOUNG E,MIELE L,TUCKER KB,et al.SU11248,a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells［J］.Cancer Biol Ther,2010,10(7):703-711.
［23］ GASPARINI G.Prognostic value of vascular endothelial growth factor in breast cancer［J］.Oncologist,2000,5(suppl_1):37-44.
［24］ SONG F,HU B,CHENG JW,et al.Anlotinib suppresses tumor progression via blocking the VEGFR2 /PI3K/AKT cascade in intrahepatic cholangiocarcinoma［J］.Cell Death Dis,2020,11(7)：573.
［25］ 徐静，陈谦，胡春霞,等.盐酸安罗替尼联合白蛋白结合型紫杉醇和顺铂方案治疗转移性三阴性乳腺癌的疗效评价［J］.中国处方药,2022,20(12):126-129. XU J，CHEN Q，HU CX，et al.Efficacy evaluation of the treatment of allotinib hydrochloride plus albumin-binding paclitaxel+cisplatin regimen for metastatic triple negative breast cancer ［J］.Journal of China Prescription Drug,2022,20(12):126-129.
［26］ 张寅斌，陈琳，陈银溪，等.化疗联合安罗替尼治疗晚期三阴性乳腺癌的疗效和安全性［J］.胸部肿瘤，2019，27(22):3986-3988.
ZHANG YB,CHEN L,CHEN YX,et al.Effectiveness and safety of chemotherapy combined with anlotinib for the treatment of advanced triple-negative breast cancer［J］.Journal of Thoracic Oncology,2019,27(22):3986-3988.
［27］ HUANG JY,XIE XF,CHEN XL,et al.A single-arm phase Ⅱ clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer［J］.Front Oncol,2023,13:1122-1294.
［28］ 聂琰,谭博,杨旭,等.化疗联合安罗替尼对三阴性乳腺癌患者的预后研究［J］.中国卫生标准管理,2021,12(2):93-95.
NIE Y,TAN B,YANG X,et al.Study on the prognosis of patients with triple negative breast cancer treated with chemotherapy combined with anlotinib［J］.China Health Standard Management,2021,12(2):93-95.
［29］ 吴军,戴明.安罗替尼联合吉西他滨＋顺铂方案治疗三阴性乳腺癌效果分析［J］.中华实用诊断与治疗杂志,2021,8(35):779-782.
WU J,DAI M.Efficacy of anlotinib combined with gemcitabine and cisplatin on triple-negative breast cancer［J］.Chinese Journal of Practical Diagnosis and Therapy,2021,8(35):779-782.
［30］ WANG JY,SUN T,OUYANG QC,et al.A phase Ⅰb study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer［J］.iScience,2023,26(6):106876.
［31］ LI HH,TAN Q,SUN S,et al.Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer(SPACE):preliminary results of a single-arm,multicenter phase Ⅱ trial ［J］.Cancer Research,2024,84(9_supplement):PO3-06-07.
［32］ SUN T,ZHANG L.A prospective phase 2 study on efficacy and safety of AK105,anlotinib combined with nab-paclitaxel(nab-P) as a first-line therapy in patients(pts) with advanced triple-negative breast cancer(TNBC) ［J］.Cancer Research,2023,83(5_supplement):OT2-08-01.
［33］ 张兴洋,杨俊兰,宫敏.安罗替尼联合化疗治疗晚期乳腺癌 10 例临床分析［J］.解放军医学院学报,2020,41(4):350-354.
ZHANG XY,YANG JL,GONG M.Effect and safety of anlotinib combined with chemotherapy for patients with advanced breast cancer:An analysis of 10 cases［J］.Acad J Chin PLA Med Sch,2020,41(4):350-354.
［34］ QIAN Y,LOU KX,ZHOU H,et al.Effificacy and safety of anlotinib based treatment in metastatic breast cancer patients［J］.Fronties in Oncology,2022,12:1042451.
［35］ HU NL,SI YR,YUE J,et al.Anlotinib has good efficacy and low toxicity:A phase Ⅱ study of anlotinib in pre-treated HER-2 negative metastatic breast cancer［J］.Cancer Biol Med,2021,18(3):849-859.
［36］ SHAO YB,LUO ZF,YU Y,et al.A real-world study of anlotinib as third-line or above therapy in patients with HER-2 negative metastatic breast cancer［J］.Frontiers in Oncology,2022,12:939343.
［37］ LIU B,LIU L,RAN J,et al.A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer［J］.ESMO Open,2023,8(3):101563.
［38］ SUN J,TANG Y,LIU X,et al.A retrospective study of anlotinib in patients with HER-2 negative metastatic breast cancer after prior two or more lines treatment ［J］.Cancer Research,2023,83(5_supplement):P4-01-13.